Pressmeddelande -
Press invitation: ATMP Sweden 2021 – COVID vaccines drive progress for patients in gene therapy
The topic of this years “ATMP Sweden 2021” conference is ‘what have we learned from the development of COVID19 vaccines that is relevant to gene therapies?’ Meet the experts that will take these experiences into the next generation of innovative medicines.
The Pfizer/BioNTech and Moderna mRNA vaccinesor the AstraZeneca and Janssen adenovirus vaccines are built on gene delivery technologies, that bring with them opportunity to ‘plug and play’ a viral gene. It is the body and not a lab that makes the viral protein to which an immune response is generated. However, if you ‘plug’ in a human gene to these technologies you no longer have a vaccine but a gene therapy, an Advanced Therapy Medicinal Product (ATMP). ATMP Sweden 2021 explores advances from raw materials to global roll that have enabled enormous strides forward in ‘gene delivery’ technologies and how this is contributing to new solutions for patients in gene therapy.
"The COVID-19 pandemic has sprinted new technologies to the benefit of mankind like we have never seen before. Gene delivery technologies, previously established in the ATMP/gene therapy field, have now become the flavour of the day for medicines that we take for granted, such as vaccines. This is truly a fantastic achievement by the scientific community and the pharmaceutical industry", says Matti Sällberg from Karolinska Institutet. Join Matti November 16th12:00 for the opening session of ATMP Sweden 2021 online.
Hosted by Sweden’s cell and gene therapy product network “ATMP Sweden”, join us online the 16th till 18th of November, 2021. See the full program below to find the sessions most relevant to you, from public vaccine acceptance to health data handling, industrial manufacture and quality, clinical implementation and future pandemic preparedness initiatives. Among others, we host the ‘big 4’ vaccine biotechs, Folkhälsomyndigheten, E-hälsomyndigheten and leaders of the Swedish Innovation hub for future needs in vaccine and ATMP manufacture, NorthX Biologics, Vinnova and the Swedish Life Sciences Office.
”Collaboration and building capacity to scale in both vaccines and ATMP will better prepare Sweden for future pandemics, while at the same time benefit patients with, for example, new gene therapy options. The innovation hub will do just this for the Nordics and will drive Sweden to be world leaders in life sciences", says Jenni Nordborg, National Life Sciences Coordinator, Government Offices of Sweden. Join Jenni November 18th 14:00 for the closing session of ATMP Sweden 2021 online.
Register here:
Contact Information:
Key person to contact in regard to press release: Annakarin Svenningsson, Communication manager, Lif – The research-based pharmaceutical industry, + 46(0)72-5274055, annakarin.svenningsson@lif.se
Key person to contact in regard to ATMP Sweden: Heather Main, Ph.D. – Communicator, +46(0)724682088 heather.main@regionstockholm.se
More information about ATMP Sweden:
This event is supported by the Vinnova funded ATMP Innovation Milieu, which aims to make Sweden ‘world leaders in ATMP by 2030’ through vision driven system innovation.
Follow ATMP Sweden: https://www.linkedin.com/company/atmpsweden
Ämnen
Lif är branschorganisationen för de forskande läkemedelsföretagen i Sverige. Vi arbetar för en högkvalitativ vård och tillgången till nya behandlingar genom att stärka den svenska Life Science-sektorn i samverkan med vårdens aktörer, politiker, tjänstemän och patientföreträdare. Lif har närmare 100 företag som medlemmar.
